Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Squalamine - NeuBase Therapeutics

X
Drug Profile

Squalamine - NeuBase Therapeutics

Alternative Names: EM0147; EVIZON; MSI-1256F; OHR 102; Squalamine lactate

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genaera Corporation
  • Developer Genaera Corporation; NeuBase Therapeutics
  • Class Antineoplastics; Cholestanols; Eye disorder therapies; Lactates; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor inhibitors; Vascular endothelial growth factor C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic macular oedema; Diabetic retinopathy; Fibrodysplasia ossificans progressiva; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Retinal vein occlusion; Wet age-related macular degeneration

Most Recent Events

  • 19 Jul 2023 EOM Pharmaceuticals plans a clinical trial in Retinal vein occlusion in USA (Ophthalmic) (EOM Pharmaceuticals website, July 2023)
  • 24 Jun 2022 EOM Pharmaceuticals plans a confirmatory phase IIb trial in Wet-age related macular degeneration and Macular oedema in Mexico and India (Ophthalmic) in first quarter of 2023 (EOM Pharmaceuticals website, July 2023)
  • 02 Dec 2021 EOM Pharmaceuticals plans a phase II trial for Diabetic retinopathy and Wet age-related macular degeneration (Ophthalmic)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top